Insmed reported $44.24M in Equity Capital and Reserves for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
DBV Technologies DBVT:US 244.42M 162.35M
Acelrx Pharmaceuticals ACRX:US $ 33.14M 71.42M
Alimera Sciences ALIM:US $ -12.34M 3.73M
Biomarin Pharmaceutical BMRN:US $ 4504.81M 113.49M
Cytokinetics CYTK:US $ 111.41M 4.85M
Dynavax Technologies DVAX:US $ 422.8M 135.32M
Gilead Sciences GILD:US $ 20215M 288M
Heron Therapeutics HRTX:US $ -21.74M 45.69M
Insmed INSM:US $ 44.24M 75.64M
Novartis NVS:US $ 62925M 1385M
Ophthotech OPHT:US $ 292.95M 40.21M
Regeneron Pharmaceuticals REGN:US $ 20687.8M 773.1M
Sarepta Therapeutics SRPT:US $ 726.46M 130.43M
Seattle Genetics SGEN:US $ 2932.81M 65.66M
Ultragenyx Pharmaceutical RARE:US $ 678.07M 118.35M
Vertex Pharmaceuticals VRTX:US $ 11933.5M 1026.5M